SEC EDGAR 6-KNov 10$LEGN

Legend Biotech Corp (LEGN): Financial results for Q3 2026

Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress

Original reporting

SEC EDGAR 6-K

Published Nov 10, 2026, 12:11 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 12:13 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$LEGN

Bullish

high confidence

Mentioned

$LEGN

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR 6-K

Decision brief

The 30-second read

$LEGNBullishHigh

Why it matters

The earnings release provides new quantitative data on sales, collaboration revenue, and a regulatory milestone, all of which were not previously public.

Market read

First‑time disclosure of earnings and IND clearance creates a fresh trading catalyst for LEGN.

What to watch

Execution risk on the IND program and competition from other CAR‑T therapies.

Relevance 7/10Novelty 8/10Timing: post-market release

Background

Legend Biotech (NASDAQ: LEGN) is a Nasdaq‑listed cell‑therapy company reporting its Q3 2026 results via a Form 6‑K filing.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LEGNBullishHigh confidence

Context

Legend Biotech released its Q3 2026 earnings with $710M CARVYKTI sales, a 36% YoY increase, and FDA IND clearance for LB2501.

Expected impact

likely upward pressure as investors price in higher sales and pipeline progress

Evidence & confidence

Quarterly results are the first public disclosure of these numbers and regulatory clearance, providing fresh material for traders.

Market effects

Sector

Positive signal for the cell‑therapy sector and potential lift for peers with CAR‑T programs.

Regional

U.S. biotech market may see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If sales growth slows after this quarter, the rally could be short‑lived.

Key entities

Company
Legend Biotech Corp
NASDAQ‑listed biotech reporting Q3 2026 results.
Executive
Ingrid Zhang
Newly appointed CEO of Legend Biotech.

Read at source ← All news

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

finance.yahoo.comNov 10

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

investing.comNov 10

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.

investing.comNov 10

MedAI 9/10

Legend Biotech Corporation Reports 100% Response Rates in 8 LB2501 Patients

Legend Biotech reported 100% response rates in 8 patients treated with LB2501 at dose level 2, with responses lasting up to 5 months. The data was presented in abstracts for the ASH 2026 conference, showing a CITADEL IEC-parkinsonism rate of 1.6% with preemptive steroids. The next catalyst is the full ASH 2026 presentations, including more Phase 1 data for LB2501 and LUCAR-G39D.

tradingview.comNov 4

$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.stOct 2

$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.comSep 25